Emerson, DMI partner to serve FDA-regulated applications

Austin, TX; Bradenton, FL – To offer production management expertise, cross-platform integration services, compliance workflow software, and life-cycle services, Emerson Process Management and Decision Management International (DMI) recently formed an alliance to extend both companies’ automation technology and services in the pharmaceutical and biotech industries. DMI provides software and implementation services for FDA-regulated manufacturers.

Emerson and DMI plan to pursue FDA-regulated automation business worldwide through joint sales, product development, and marketing efforts. The combined solutions offering will deliver advanced process automation and workflow compliance applications, and will integrate process and manufacturing execution information to help manufacturers reduce product cycle times, realize cost savings, and comply with cGxP practices. The term cGXP refers to U.S. FDA definitions for current Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and Good Manufacturing Practices (GMP).

As part of their alliance’s resale and systems integration section, Emerson will combine its pharmaceutical industry expertise, engineering resources, and project management capabilities, as well as its PlantWeb digital plant architecture, with DMI’s Web-based software and service solutions, Regulus. The companies will also participate in a joint development project to integrate Regulus with Emerson’s DeltaV digital automation, which is PlantWeb’s host system.

Do you have experience and expertise with the topics mentioned in this content? You should consider contributing to our WTWH Media editorial team and getting the recognition you and your company deserve. Click here to start this process.